Patents by Inventor Steven A. Titus

Steven A. Titus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132160
    Abstract: A component for a vehicle includes a skid plate configured to attach to an underbody of the vehicle, a plurality of cooling channels extending in a longitudinal direction between the skid plate and the underbody of the vehicle, and a structural reinforcement extending outward from the skid plate. The skid plate, the plurality of cooling channels, and the structural reinforcement are additively manufactured in a unitary construction.
    Type: Application
    Filed: October 18, 2022
    Publication date: April 25, 2024
    Applicant: Ford Global Technologies, LLC
    Inventors: Keith Weston, Jim Stevens, David D. Friske, Mark Meinhart, Matthew Arthur Titus
  • Patent number: 10301314
    Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 28, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern University
    Inventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng, Chen Wang
  • Publication number: 20170260192
    Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Applicants: The United States of America, as represented by the Secretary, Dept of Health and Human Services, University of Kansas, Northwestern University
    Inventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
  • Patent number: 9663521
    Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: May 30, 2017
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Kansas, Northwestern University
    Inventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
  • Patent number: 9458141
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: October 4, 2016
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Forschungsverbund Berlin, E.V.
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
  • Patent number: 9296729
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: March 29, 2016
    Assignees: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Forschungsverbund Berlin E.V.
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wenwei Huang, Gerd Krause, Gunnar Kleinau, Wei Zheng
  • Publication number: 20160024023
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Application
    Filed: September 29, 2015
    Publication date: January 28, 2016
    Applicants: Health and Human Services, Forschungsverbund Berlin E.V.
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
  • Patent number: 9187457
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 17, 2015
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Forschungsverbund Berlin E.V.
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
  • Publication number: 20140323438
    Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.
    Type: Application
    Filed: December 17, 2012
    Publication date: October 30, 2014
    Inventors: Kevin Frankowski, Samarjit Patnaik, Sui Huang, Juan Jose Marugan, John Norton, Frank J. Schoenen, Noel Terrence Southall, Steven Titus, Wei Zheng
  • Publication number: 20140301944
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 9, 2014
    Applicants: Forschungsverbund Berlin E.V., The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wenwei Huang, Gerd Krause, Gunnar Kleinau, Wei Zheng
  • Patent number: 8741259
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: June 3, 2014
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
  • Publication number: 20130251631
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 26, 2013
    Applicants: Forschungsverbund Berlin E.V., The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
  • Publication number: 20130096160
    Abstract: Aryl substituted thiazol-2-yl-piperidines and related compounds useful as modulators of survival motor neuron (SMN) protein production are provided herein. Without being bound to any particular theory it is believed the aryl substituted thiazol-2-yl-piperidines and related compounds provided herein act to increase production of the SMN2 form of survival motor neuron protein. These compounds are useful for treating spinal muscular atrophy. Pharmaceutical compositions containing a carrier and one or more of the aryl substituted thiazol-2-yl-piperidine or related compounds described herein are also provided. Methods of treating spinal muscular atrophy are also provided by this disclosure.
    Type: Application
    Filed: April 14, 2011
    Publication date: April 18, 2013
    Applicants: Secretary, Department of Health and Human Services
    Inventors: Juan Jose Marugan, Jingbo Xiao, Steven A. Titus, Noel Southall, Wei Zheng, Elliot J. Androphy, Jonathan Cherry
  • Publication number: 20110195018
    Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
    Type: Application
    Filed: October 20, 2008
    Publication date: August 11, 2011
    Inventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
  • Patent number: 7126403
    Abstract: A new clock driver is described for the use in the phase detector of a clock and data recovery circuit (CDR). By building a resonant LC tank, whose center frequency is similar to the clock frequency, a low power clock driver is realized. A method based upon minimizing power consumption is described for determining the value of the programmable capacitance. A programmable capacitance adjusts the center frequency of the tank so it matches the frequency of the clock and a finite state machine at startup determines the value of this programmable capacitance. A criterion for tuning the center frequency of the tank is to choose the capacitance which leads to the lowest power consumption. A low Q tank affords a reasonable compromise between power efficiency and performance in the CDR circuit.
    Type: Grant
    Filed: November 1, 2004
    Date of Patent: October 24, 2006
    Assignee: Analog Devices, Inc.
    Inventors: John G. Kenney, Jr., Viswabharath Reddy, Ward Steven Titus
  • Patent number: 6087488
    Abstract: Novel genes in the erg subfamily of potassium channel proteins in humans are described. This family of proteins, and the genes encoding the proteins, are implicated in the development of long Q-T syndrome, a rare, but often fatal, cardiac arrhythmia.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: July 11, 2000
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Barry S. Ganetzky, Steven A. Titus
  • Patent number: 5986081
    Abstract: Novel genes in the erg subfamily of potassium channel proteins in humans are described. This family of proteins, and the genes encoding the proteins, are implicated in the development of long Q-T syndrome rare, but often fatal, cardiac arrhythmia.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: November 16, 1999
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Barry S. Ganetzky, Steven A. Titus